Provepharm Inc. / U.S. Food, 2024-02: The boxed warning on the FDA-approved injectable methylene blue label tells prescribers to avoid concomitant use with SSRIs, SNRIs, MAOIs and opioids because of serious or fatal serotonin syndrome.
PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. Avoid concomitant use of PROVAYBLUE with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs) and opioids
1
Provepharm Inc. / U.S. Food, 2024-02: The boxed warning on the FDA-approved injectable methylene blue label tells prescribers to avoid concomitant use with SSRIs, SNRIs, MAOIs and opioids because of serious or fatal serotonin syndrome. PDF, Revised: 02/2024. Boxed warning, page 1. Quote wraps across lines in the PDF; whitespace normalised for substring check. Also filed as MTC-119, MTC-088, MTC-118, MTC-110 (claims C14, F3, F5, F7, F8). Study type: regulatory record.
